Table 2.
Summary of the most recent case reports including case 1 (patient A)a and 2 (patient B)b. n = 14
| Sex/Age | Cardiac marker | ECG | Echo | MRI | Antibiotics | Outcome |
|---|---|---|---|---|---|---|
| M/24a | TnT 504 ng/L | ST-elevation | Normal, LVEF 60–65 % | No | Azithromycin | Full recovery |
| M/23b | TnT 128 ng/L | Normal | Normal incl LVEF | No | Azithromycin | Full recovery |
| M/60 [6] | N/A | N/A | Pericard effusion | No | Ceftriaxone/Meropenem | Diarroea |
| M/43 [7] | TnT 1.75 ng/ml | ST-elevation | Abn wall motion LVEF 68 % | Subepi/myocardial enhancement | Azithromycin | N/A |
| M/33 [8] | TnI 18.6mcg/L | ST-elevation | LVEF 56 % | Increased signal subepi, dilated LV/RV | Roxithromycin | N/A |
| M/17 [9] | TnI 16.8 ng/mL | ST-elevation | Normal | Subepicardial enhancement | Azithromycin | Full recovery |
| M/21 [5] | TnI 15.6 ng/ml | Normal | Decreased LVEF | Subepi/myocardial enhancement | Azithromycin | Almost full rec |
| M/24 [5] | TnI 8.9 mcg/L | ST-elevation | LVEF 40 % | Subepicardial enhancement | No | Full recovery |
| M/42 [5] | TnI 11.6mcg/L | ST-elevation | LVEF 40 % | Subepicardial enhancement | Ciprofloxacin | Full recovery |
| M/21 [10] | TnI 39.8mcg/L | ST-elevation | Normal inkc LVEF | No | Ciprofloxacin | Full recovery |
| M/21 [11] | TnI 2.5mcg/L | ST-elevation | Normal incl LVEF | No | Yes(unknown kind) | Full recovery |
| M/24 [12] | CK normal | Arrythmia | Decreased LVEF/peric effusion | No | Roxithromycin | N/A |
| M/19 [13] | TnT 0.52 ng/mL | Strain | N/A | Yes | N/A | N/A |
| M/16 [14] | TnT 1.7 ng/mL | ST-elevation | LVEF 45 % | No | Clarythromycin | Full recovery |
| M/17 [14] | TnT 0.9 ng/mL | ST-elevation | Normal incl LVEF | Myocardial enhancement | Clarythromycin | Full recovery |